Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neurostim Treatment Shows Promise As Psychiatric Treatment, Doc Says

This article was originally published in The Gray Sheet

Executive Summary

Implanting a device to stimulate the nervous system with electrical current promises to be as viable a treatment for psychiatric conditions as it has proven for movement disorders, according to Ali Rezai, MD, chair of the Cleveland Clinic Center for Neurological Restoration

You may also be interested in...



St. Jude Starts Pivotal Depression Trial For Deep Brain Stimulator

St. Jude Medical officially entered the race Feb. 7 to successfully market an implantable neurostimulator for depression, announcing FDA clearance for a pivotal trial testing its Libra deep brain stimulation device for the indication

St. Jude Starts Pivotal Depression Trial For Deep Brain Stimulator

St. Jude Medical officially entered the race Feb. 7 to successfully market an implantable neurostimulator for depression, announcing FDA clearance for a pivotal trial testing its Libra deep brain stimulation device for the indication

Devices shine in Cleveland Clinic’s “Top 10”

Neurostimulation for psychiatric disorders comes in at No. 3 on Cleveland Clinic's list of medical innovations likely to have a significant impact on healthcare in 2007, unveiled Nov. 7 at the institution's 2006 Medical Innovations Summit. Center for Neurology Restoration Chair Ali Rezai, MD, notes that mental disorders account for 15% of the disease burden in the U.S. - more than all cancers combined - and four of the ten leading causes of disability in developed countries. Developers include Medtronic, investigating the use of deep brain stimulation to treat depression and obsessive compulsive disorder (1"The Gray Sheet" May 22, 2006, p. 7). Non-pulsatile left ventricular assist devices also made the list (No. 9), while the 4, 5 and 7 spots went to optical coherence tomography for treating and diagnosing eye diseases, bronchial thermoplasty for treating asthma, and endografting for treating vascular disease, respectively. The other top spots went to drugs...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023578

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel